New views on rejection mechanisms and their relevance to interleukin-2 as a treatment for renal cell cancer.
Oliver
R T
RT
Department of Medical Oncology, London Hospital Medical College, University of London.
D002292:Carcinoma, Renal Cell / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000276:immunology* / Q000628:therapy
D007376:Interleukin-2